Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
MESO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.08 - $22.00
Previous CloseN/A
Volume155.35K
Average Volume (3M)326.79K
Market Cap
$1.79B
Enterprise ValueN/A
Total Cash (Recent Filing)$48.40M
Total Debt (Recent Filing)$114.61M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
May 28, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding127,052,720
10 Day Avg. Volume326,245
30 Day Avg. Volume326,794
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)269.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$27.00Price Target Upside93.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Mesoblast News
PremiumCompany Announcements
Mesoblast’s Earnings Call: RYONCIL Approval & Growth
PremiumCompany Announcements
Mesoblast Reports FDA Approval and Financial Results
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA approval of Ryoncil represents a watershed moment for Mesoblast, leading to a reduction in revenue risk adjustment and an increase in the 12-month price target.
Market OpportunityRyoncil is positioned for a market opportunity of approximately $500 million due to the high pricing range similar to CAR-T and gene therapy, driven by the high unmet need in pediatric SR-aGvHD.
Pipeline ExpansionSignificant potential for Mesoblast in its late-stage pipeline, including heart failure (HF), with potentially two near-term filings, as well as the ongoing P3 in chronic lower back pain (CLBP).
Bears Say
Competitive LandscapeRyoncil's approval as the only drug for patients under 12 could provide a competitive advantage, especially in the 12-18 year-old segment where it overlaps with Jakafi.
Market RiskThe market for adult 2L SR-aGvHD could be twice the size of the pediatric market, as MESO targets patients who fail Jakafi treatment.
Regulatory ChallengesThe committee voted 9-1 in favor of the data package supporting approval despite earlier negative briefing documents.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.42% Other Institutional Investors
98.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MESO FAQ
What was Mesoblast Ltd’s price range in the past 12 months?
Mesoblast Ltd lowest stock price was $2.08 and its highest was $22.00 in the past 12 months.
What is Mesoblast Ltd’s market cap?
Mesoblast Ltd’s market cap is $1.79B.
When is Mesoblast Ltd’s upcoming earnings report date?
Mesoblast Ltd’s upcoming earnings report date is May 28, 2025 which is in 64 days.
How were Mesoblast Ltd’s earnings last quarter?
Mesoblast Ltd released its earnings results on Feb 26, 2025. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.275 by -$0.145.
Is Mesoblast Ltd overvalued?
According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued.
Does Mesoblast Ltd pay dividends?
Mesoblast Ltd does not currently pay dividends.
What is Mesoblast Ltd’s EPS estimate?
Mesoblast Ltd’s EPS estimate is -0.14.
How many shares outstanding does Mesoblast Ltd have?
Mesoblast Ltd has 127,052,720 shares outstanding.
What happened to Mesoblast Ltd’s price movement after its last earnings report?
Mesoblast Ltd reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.275. Following the earnings report the stock price went down -1.145%.
Which hedge fund is a major shareholder of Mesoblast Ltd?
Currently, no hedge funds are holding shares in MESO
---
Mesoblast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.00 (93.69% Upside)
$27.00 (93.69% Upside)
Blogger Sentiment
Bullish
MESO Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
516.81%
12-Months-Change
Fundamentals
Return on Equity
-21.26%
Trailing 12-Months
Asset Growth
-2.53%
Trailing 12-Months
Company Description
Mesoblast Ltd
Mesoblast Limited is a biopharmaceutical company focused on developing and commercializing innovative cellular medicines. It specializes in regenerative medicine, utilizing its proprietary mesenchymal lineage cell technology platform to treat complex diseases resistant to conventional therapies. The company operates primarily in the biotechnology sector, with a focus on developing treatments for conditions such as chronic heart failure, acute respiratory distress syndrome, chronic low back pain, and inflammatory conditions.
---
MESO Company Deck
---
MESO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements including the FDA approval of RYONCIL, successful fundraising, and promising clinical trial results. However, the company faces some challenges such as non-cash balance sheet impacts and ongoing trial enrollments.Read More>---
MESO Stock 12 Month Forecast
Average Price Target
$27.00
▲(93.69% Upside)
Technical Analysis
Best Analysts Covering MESO
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
+15.41%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +15.41% per trade.
---